Huadong Medicine submitted the IND application for HDP-101, an anti-BCMA Antibody-Drug Conjugate, in China. In 2022, Huadong Medicine acquired Asia (excluding Japan) rights for HDP-101 and HDP-103, which is an anti-PSMA ADC, from Heidelberg . The agreement also included an exclusive opt-in right for two additional candidates, amounting to a total of 930 million USD. HDP-101 HDP-101 is a novel ADC targeting BCMA linked to amanitin as a payload with a DAR of 2. The product is under-investigated in the phase 1/2 clinical study in patients with multiple myeloma. HDP-101 During the 2024 AACR Annual Meeting, Heidelberg presented the stage 1 results of a clinical trial. There were no dose-limiting toxicities (DLT) among the first 4 cohorts, but 3 DLTs related to thrombocytopenia occurred in cohort 5. The dose optimization for cohort 5 is still ongoing. Regarding the efficacy, 1 patient in cohort 3 archived stable disease. In cohort 5, 2 patients archived PR, and 2 have SD. Th...
China Biotech XYZ Shares Updates Related to New Drug Development in China